99 related articles for article (PubMed ID: 20514405)
1. Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.
Pierigè F; De Marco C; Orlotti N; Dominici S; Biagiotti S; Serafini S; Zaffaroni N; Magnani M; Rossi L
Int J Oncol; 2010 Jul; 37(1):133-42. PubMed ID: 20514405
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Fraternale A; Rossi L; Magnani M
Biochim Biophys Acta; 1996 Oct; 1291(2):149-54. PubMed ID: 8898876
[TBL] [Abstract][Full Text] [Related]
3. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay.
Ajani JA; Tomasovic B; Spitzer G; Kavanagh JJ; Thielvoldt D; Baker FL; Gershenson D
Invest New Drugs; 1986; 4(2):141-8. PubMed ID: 2426218
[TBL] [Abstract][Full Text] [Related]
4. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
5. Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.
Umbach GE; Hug V; Spitzer G; Thames H; Drewinko B
Invest New Drugs; 1984; 2(3):263-5. PubMed ID: 6210262
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of fludarabine (2-fluoro-ara-AMP).
Kavanagh JJ; Krakoff IH; Bodey GP
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of salvage pathway enzymes by adenine arabinoside 5'-monophosphate (ara-AMP).
Becher HJ; Schollmeyer P
Klin Wochenschr; 1983 Aug; 61(15):751-7. PubMed ID: 6194338
[TBL] [Abstract][Full Text] [Related]
8. Glycodendrimer Nanocarriers for Direct Delivery of Fludarabine Triphosphate to Leukemic Cells: Improved Pharmacokinetics and Pharmacodynamics of Fludarabine.
Gorzkiewicz M; Jatczak-Pawlik I; Studzian M; Pułaski Ł; Appelhans D; Voit B; Klajnert-Maculewicz B
Biomacromolecules; 2018 Feb; 19(2):531-543. PubMed ID: 29323872
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J
Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681
[TBL] [Abstract][Full Text] [Related]
11. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Boldt DH; Von Hoff DD; Kuhn JG; Hersh M
Cancer Res; 1984 Oct; 44(10):4661-6. PubMed ID: 6205751
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antiproliferative potency of 9-beta-D-arabinofuranosyl-2-fluoroadenine phospholipid adducts.
Brachwitz H; Bergmann J; Thomas Y; Wollny T; Langen P
Bioorg Med Chem; 1999 Jun; 7(6):1195-200. PubMed ID: 10428391
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
[TBL] [Abstract][Full Text] [Related]
14. Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
Bogdahn U; Zapf J; Weber H; Dünisch G; Löbering HG; Martin R; Mertens HG
Br J Cancer; 1987 Feb; 55(2):153-8. PubMed ID: 2434122
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and action of fludarabine phosphate.
Plunkett W; Huang P; Gandhi V
Semin Oncol; 1990 Oct; 17(5 Suppl 8):3-17. PubMed ID: 1699280
[TBL] [Abstract][Full Text] [Related]
16. Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin.
Fiume L; Busi C; Di Stefano G; Mattioli A; Torrani-Cerenzia M; Bonino F; Capra G; De Bernardi W; Ponzetto A; Lavezzo B
Ital J Gastroenterol; 1995 May; 27(4):189-92. PubMed ID: 8520036
[TBL] [Abstract][Full Text] [Related]
17. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
Sampath D; Plunkett W
Cancer Res; 2000 Nov; 60(22):6408-15. PubMed ID: 11103806
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic analysis of the ip administration of fludarabine phosphate in the swine.
Weiss GR; Gaskill HV; Phillips JL
Cancer Treat Rep; 1986 Apr; 70(4):499-502. PubMed ID: 2421893
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of fludarabine phosphate (F-ara-AMP).
Casper ES; Mittelman A; Kelson D; Young CW
Cancer Chemother Pharmacol; 1985; 15(3):233-5. PubMed ID: 2414021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
